Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Biosyent ( (TSE:RX) ) has issued an announcement.
BioSyent Inc. reported strong financial results for the fourth quarter and full year 2024, with significant growth in Canadian pharmaceutical sales and a notable increase in EBITDA and net income. The acquisition of global rights to Tibelia® (tibolone) and the transition of its distribution to BioSyent’s structure are expected to diversify revenue streams and enhance profitability. The company also maintained its commitment to shareholders by returning $7.3 million through dividends and share buybacks, marking its 15th consecutive year of profitability.
More about Biosyent
BioSyent Inc. is a growth-oriented specialty pharmaceutical company listed on the TSX Venture Exchange under the symbol ‘RX’. It focuses on in-licensing or acquiring innovative pharmaceutical and healthcare products that are safe, effective, and have a proven track record of improving patient lives. The company markets its products through community, specialty, and international business units.
YTD Price Performance: -1.37%
Average Trading Volume: 4,136
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$124M
Find detailed analytics on RX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue